Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G; LIS2T Study Group. Levy G, et al. Among authors: samuel d. Transplantation. 2004 Jun 15;77(11):1632-8. doi: 10.1097/01.tp.0000129095.51031.42. Transplantation. 2004. PMID: 15201658 Clinical Trial.
Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation.
Samuel D, Bismuth H, Boillot O, Ducerf C, Baulieux J, Gugenheim J, Baldini E, Launois B, Messner M, Wolf P, Ellero E, Domergue J, Pageaux J, Cherqui D, Duvoux C, Durand F, Belghiti J, Calmus Y, Massault PP, Neau-Cransac M, Saric J, LeTreut Y, Campan P. Samuel D, et al. Transplant Proc. 1998 Jun;30(4):1394-6. doi: 10.1016/s0041-1345(98)00286-3. Transplant Proc. 1998. PMID: 9636563 Clinical Trial. No abstract available.
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L. Levy G, et al. Among authors: samuel d. Liver Transpl. 2006 Nov;12(11):1640-8. doi: 10.1002/lt.20707. Liver Transpl. 2006. PMID: 16598777 Free article. Clinical Trial.
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA. Levy G, et al. Among authors: samuel d. Liver Transpl. 2006 Oct;12(10):1464-72. doi: 10.1002/lt.20802. Liver Transpl. 2006. PMID: 17004259 Free article. Clinical Trial.
Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study.
Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, Rostaing L, Rimola A, Marshall S, Mayer AD; ReSpECT Study Group. Neuberger JM, et al. Among authors: samuel d. Am J Transplant. 2009 Feb;9(2):327-36. doi: 10.1111/j.1600-6143.2008.02493.x. Epub 2008 Dec 15. Am J Transplant. 2009. PMID: 19120077 Free article. Clinical Trial.
Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients.
Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P, Samuel D, Vanlemmens C, Neau-Cransac M, Salamé E, Chazouillères O, Declerck N, Pageaux GP, Dubel L, Rostaing L. Calmus Y, et al. Among authors: samuel d. Transplantation. 2010 Jun 27;89(12):1504-10. doi: 10.1097/TP.0b013e3181db8cf0. Transplantation. 2010. PMID: 20495510 Clinical Trial.
1,218 results